Verici Dx plc (VRCI.L) Stock

VRCI.L logo

Verici Dx plc

VRCI.LUnited Kingdom
Healthcare

Company profile

Verici Dx reports about 23 full-time employees.

Figures from company filings; latest fiscal year ended December 31, 2024.

About Verici Dx plc

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs; and functional binding multicell assay. In addition, the company provides bioinformatics and data science services for exome analysis options; RNA pipeline; multiomic signature discovery, TCR clonotype antigen identification, custom pipeline building, and predictive modeling; and simulation of drug combinations against multiomic personalized tumor models. It has collaborations with One Lambda Inc. for the commercialization of pre transplant risk assessment (PTRA), a pre-transplant prognosis test for the risk of early acute rejection; The Westmead Institute for Medical Research to determine the factors contributing to graft loss in organ transplants; and FBB Biomed, Inc., which provides research-use-only tests for clinicians seeking insights into neurologic diseases, such as multiple sclerosis and long COVID. Verici Dx plc was incorporated in 2020 and is headquartered in Cardiff, the United Kingdom.

Largest shareholders

  • Puma Investment Management Ltd.10.48%
  • UBS Asset Management (UK) Ltd.8.92%
  • Unicorn Asset Management Ltd.8.35%
  • Canaccord Genuity Wealth Ltd.6.55%
  • Harwood Capital LLP2.54%

Share of the company, as of September 25, 2026

Leadership

  • Sara jane Barrington A.C.A., A.C.I.M. — CEO & Executive Director, 58
  • David Mark Anderson — CFO & Company Secretary, 62
  • Keith Gilliard — Senior Director of Sales

What companies are similar to Verici Dx?

Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include ConvaTec Group PLC (CTEC.L), Advanced Medical Solutions Group plc (AMS.L), SDI Group plc (SDI.L).

Company Information

SectorHealthcare
IndustryVarious Healthcare Equipment Manufacturing
Employees23
Founded2020
IPO DateNov 3, 2020
IPO StatusPublic
HeadquartersCardiff, United Kingdom
ExchangeLSE
TimezoneEurope/London (GMT)

Contact & Links

Address
Avon House, Cardiff, CF64 2EZ
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Verici Dx plc (VRCI.L)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/VRCI.L

LinkedInLinkedInXXYouTubeYouTube